Pure Global
NCT06414044

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)
University of Florence·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine
Drug/Device/Intervention
Atogepant 60 mg
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
University of Florence
Location
Florence,Roma, Italy
Timeline & enrollment
Phase
N/A
Start date
May 09, 2024
End date
Apr 01, 2026
Enrollment
100 participants
Primary outcome

Changes in migraine frequency after three months of treatment,50% Response after three months of treatment

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and
 tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic
 migraine patients.

ICD-10 classifications
Migraine without aura [common migraine]Migraine with aura [classical migraine]Other migraineMigraineMigraine, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414044
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414044 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Recruiting. The study focuses on Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.